Cellectis (CLLS) Long-Term Investments (2019 - 2026)
Cellectis (CLLS) recorded quarterly Long-Term Investments of $4.8 million in Q1 2026, down 5.27% quarter-over-quarter from $5.1 million in Q4 2025, and down 8.4% on a YoY basis from $5.3 million in Q1 2025.
Cellectis (CLLS) Long-Term Investments (2019 - 2026) Analysis & Trends
Cellectis' Long-Term Investments history runs 8 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Long-Term Investments fell 8.4% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 8.4% YoY), while the FY2025 annual figure was $5.1 million, down 32.35% from the prior year.
- Long-Term Investments was $4.8 million for Q1 2026 at Cellectis, down from $5.1 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $35.7 million in Q3 2025 to a low of $4.8 million in Q1 2026.
- Historically, Long-Term Investments has averaged $12.0 million across 5 years, with a median of $8.1 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Long-Term Investments surged 710.0% in 2022, then slumped 53.98% in 2024.
- A 5-year view of Long-Term Investments shows it stood at $8.1 million in 2022, then retreated by 3.05% to $7.9 million in 2023, then decreased by 4.23% to $7.5 million in 2024, then tumbled by 32.35% to $5.1 million in 2025, then decreased by 5.27% to $4.8 million in 2026.
- The last three Long-Term Investments figures came in at $4.8 million (Q1 2026), $5.1 million (Q4 2025), and $35.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 4.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.82 Mn |
| Dec 31, 2025 | 5.09 Mn |
| Sep 30, 2025 | 35.74 Mn |
| Jun 30, 2025 | 35.49 Mn |
| Mar 31, 2025 | 5.26 Mn |
| Dec 31, 2024 | 7.52 Mn |
| Sep 30, 2024 | 7.65 Mn |
| Jun 30, 2024 | 16.65 Mn |
| Mar 31, 2024 | 7.87 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Sep 30, 2023 | 16.62 Mn |
| Jun 30, 2023 | 13.01 Mn |
| Mar 31, 2023 | 8.19 Mn |
| Dec 31, 2022 | 8.10 Mn |
| Sep 30, 2022 | 8.93 Mn |
| Jun 30, 2022 | 9.09 Mn |
| Mar 31, 2022 | 6.57 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Dec 31, 2020 | 1.00 Mn |
| Dec 31, 2019 | 5.00 Mn |